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We cloned the heavy- and light-chain variable domains of two monoclonal antibodies that recognize each of the two major
neutralizing antigenic sites of the canine parvovirus (CPV) capsid. After expression in Escherichia coli as single-chain variable
domains (scFv) with glycine-serine linker sequences, both scFv bound CPV capsids with the same specificity as the intact
IgG, but with 10- to 20-fold lower avidity. Both scFvs neutralized CPV infectivity with efficiency similar to that of the IgG.
Although both IgGs inhibited hemagglutination by CPV, only one scFv was inhibiting. The binding of one of the antibodies has
previously been analyzed by cryoelectron microscopic reconstruction and the epitope-binding residues predicted. Mutagen-
esis of predicted contact residues in three heavy-chain complementarity-determining regions (CDR) showed that mutants of
CDR1 or CDR3 reduced the binding of the scFv by about 10-fold compared with the wild-type scFv, while no effect was seen
for one mutant of CDR2. The levels of neutralization of CPV and of hemagglutination inhibition by the scFv mutants were
proportional to their reduction in binding affinity compared with the wild type. Neither scFv blocked virus binding to host cells,
but they both caused aggregation of the capsids and appeared to affect the process of infection after virus uptake into the
cells. © 2000 Academic Press
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Antibodies are a major host defense against many
viruses in vertebrates, and the mechanisms of interac-
tion between the antibodies and viral antigens are now
becoming understood. The interactions involve antibody
binding to the viral structures in a number of different
ways, including binding to flexible loops (Logan et al.,
1993; Verdaguer et al., 1999) or to structures that are
etermined by the folded polypeptide (Colman et al.,
987; Malby et al., 1993; Bizebard et al., 1995; Che et al.,
998; Malby et al., 1998). The mechanisms of virus neu-
ralization can include virus aggregation, masking of re-
eptor attachment sites, steric inhibition of receptor
inding, or stabilization of the capsid to inhibit virus
ncoating (Outlaw and Dimmock, 1991; Smith, 1993; Ver-
aguer et al., 1997; Fleury et al., 1999; Sattentau et al.,
1999; Smith and Baker, 1999).
The specific interactions between antibodies and an-
tigens involve multiple contacts between the antibody-
combining site and the epitope (Davies et al., 1990).
When examined at high resolution, changes in the struc-
tures of both the viral epitope and the antibody-combin-
ing site that allow the effective binding are seen (Colman
et al., 1987; Bizebard et al., 1995; Smith and Baker, 1999).
Antigenic variants of many viruses can arise throughA
c
1 To whom correspondence and reprint requests should be ad-
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471single-sequence substitutions within antibody-combin-
ing sites, and those viruses often show reduced or no
neutralization by the antibodies (Harris et al., 1977; Wiley
et al.,1981; Sobrino et al., 1989; Strassheim et al., 1994;
Fleury et al., 1998). That variation may be constrained by
the ability of the virus to accommodate structural varia-
tion, and viruses differ in their ability to naturally change
their antigenic properties.
The parvovirus capsid is 26 nm in diameter, is made
up of 60 copies of a combination of VP1 and VP2 pro-
teins, and has T 5 1 icosahedral symmetry (Tsao et al.,
1991; Xie and Chapman, 1996; Weichert et al., 1998).
Capsid structures have been determined for canine par-
vovirus (CPV), for the antigenically variant feline panleu-
kopenia virus (FPV), and for a CPV mutant with VP2
residue 300 Ala changed to Asp (Tsao et al., 1991; Ag-
bandje et al., 1993; Wu and Rossmann, 1993; Llamas-Saiz
et al., 1996). The CPV antigenic structure has also been
examined using peptide analysis and by monoclonal
antibody (MAb) analysis of antigenically variant viruses
(Lopez de Turiso et al., 1991; Langeveld et al., 1993;
trassheim et al., 1994). The variant virus analysis
howed two major neutralizing antigenic sites (termed
ites A and B) that were recognized by many MAbs, and
atural variants of both sites A and B have been selected in
ature (Parrish et al., 1985, 1991; Strassheim et al., 1994).
The binding of one MAb (MAb 8, also referred to as
3B10) to site B was examined using cryoelectron mi-
roscopy, mutations within the B antigenic site have
0042-6822/00 $35.00
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472 YUAN AND PARRISHbeen defined, and the structure of a CPV mutant that did
not bind MAb 8 has been solved (Wikoff et al., 1994;
lamas-Saiz et al., 1996; Parker and Parrish, 1997). The
Ab 8 Fab protrudes from the virus with the long axis in
radial direction but leaning away from the nearest
wofold axis, indicating that bivalent binding of one IgG to
single capsid would not occur. The two variable do-
ains straddle a ridge on the CPV surface composed of
esidues 296 to 303, within which two escape mutations
ave been located (VP2 residue 300 Ala to Asp and
esidue 302 Asn to Asp) (Strassheim et al., 1994; Llamas-
aiz et al., 1996).
Antibodies and antigens interact through extensive
ontacts between the complementarity-determining re-
ions (CDRs) of the light and heavy chains of the anti-
odies and the antigen. The contacts between the heavy-
hain CDRs and antigen generally are more extensive,
nd VH CDR3 is often particularly important in determin-
ng the antigen specificity (Braden and Poljak, 1995;
adlan et al., 1995). For MAb 8 the VH CDR1 and CDR3
ppeared to make contacts with the CPV surface,
hrough Asp31 and Tyr32 in CDR1, Asn52 in CDR2, and
ly100 and Tyr101 in CDR3 (Wikoff et al., 1994).
Bacterial expression of an antibody variable domain
llows for production of a single-chain variable fragment
scFv), and those expressed domains provide useful
ools for studying antibody structure and functions
Skerra et al., 1991; Raag and Whitlow, 1995).
To define the mechanisms of antibody specificity, and
o analyze the binding and neutralization of CPV, we
loned the variable domains of MAbs which recognize
he CPV A (MAb 14) or B (MAb 8) antigenic sites. These
ariable domains were expressed in bacteria as scFv,
nd they had binding properties similar to those of the
Ab from which they were derived. Both scFvs efficiently
eutralized CPV infectivity, but only one of them inhibited
iral hemagglutination (HA). Mutagenesis of heavy-chain
DRs of one scFv confirmed that residues important for
inding the B antigenic site were within both the heavy-
hain CDR1 and the CDR3. Mechanisms of neutralization
ncluded aggregation of the capsids and inhibition of
nfection after binding and entry into cells.
RESULTS
ariable region cloning, sequencing, and expression
The variable domain cDNA sequences of the heavy-
VH) and light-chain (VL) genes of MAb 8 and MAb 14
ere amplified from mRNA by RT-PCR, cloned into plas-
ids, and sequenced. By use of the Sequence Sub-
rouping program in the Kabat database, the VH of MAb
8 was grouped within the miscellaneous subgroup, and
the VH of MAb 14 was within subgroup IIB. Both MAbs
contained the k light chain: the VL of MAb 8 was in
ubgroup VI; the VL of MAb 14 was in subgroup I. The
s
hDR assignment within the MAb sequences was based
n the Kabat numbering scheme (Fig. 1). The variable
omain sequences were recloned into the expression
ector pET22b(1) by overlapping extension PCR, adding
he pel B signal sequence and a six-histidine C-terminal
tag (Fig. 2). Clones of both scFvs were obtained with
either two or three repeats of the Gly-Gly-Gly-Gly-Ser
linker sequence. Both scFvs containing the three-repeat
linker were expressed in bacteria, and the molecular
weights of those on the SDS–PAGE appeared close to
the predicted sizes (results not shown). When versions of
the scFvs that contained two copies of the G4S linker
sequence were tested, that derived from the MAb 8 clone
still bound to CPV, whereas the scFv from MAb 14 did not
bind to any detectable degree (results not shown). Those
results are similar to those reported for other antibodies
in which the ability of the VH and VL domains to associate
orrectly was determined by the length of the linker
equence (Malby et al., 1993; Raag and Whitlow, 1995).
he scFvs bound CPV with the same specificity as
he original MAb and neutralized CPV infectivity
Purified bacterially expressed scFvs were tested for
inding in ELISA to CPV or FPV capsids, or to denatured
PV capsids, and compared with the intact MAbs. Each
cFv bound to CPV with the same specificity as the
riginal MAb, as scFv-8 bound efficiently to both CPV
nd FPV but not to the denatured capsids, while scFv-14
ound to CPV, but not to FPV or to denatured CPV
apsids (Fig. 3). However, the binding efficiencies of both
cFv were 10- to 20-fold lower than that of the original
Ab (Figs. 3A and 3B).
The scFvs were tested for neutralization of CPV infec-
ivity on A72 cells and NLFK cells by TCID50 assay. The
Ab and scFv all showed similar efficiencies of neutral-
zation of CPV when tested on NLFK cells (Fig. 4A) or on
72 cells (results not shown).
cFv-8, but not scFv-14, inhibited viral HA
MAb 8 and MAb 14 both inhibit viral HA (Table 1)
Strassheim et al., 1994). scFv-8 inhibited HA with a
0-fold reduced efficiency compared with MAb 8 (Table
). However, scFv-14 did not show any HA inhibition even
t 400 nM, while MAb 14 inhibited 4 HA units of CPV at
.125 nM (Table 1). When anti-Fab antibody was added to
he reaction, the efficiency of HA inhibition by both scFvs
ncreased, as scFv-8 showed HA inhibition at 0.0625 nM
nd scFv-14 was active at 10 nM.
utations in VH CDRs of scFv-8 reduced the binding
ffinity, neutralization efficiency, and HA inhibition
Changing one or two predicted contact residues in
cFv-8 CDR H1, H2, or H3 gave scFv that still bound virus;
owever, when tested in competition ELISA the H1 and
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473CPV ANTIBODIES AND NEUTRALIZATIONH3 mutants bound to CPV with about 10-fold lower affin-
ity than wild type, while the H2 mutant binding was the
same as wild type (Fig. 5B). The scFv-8 with a combina-
tion of the H1 and H3 mutations bound about 2-fold less
efficiently than either of those single mutants, while the
H1 or H3 mutation along with the H2 mutation showed no
additional effect on binding compared with the H1 or H3
mutation alone (Fig. 5B).
The three mutants which showed reduced binding
affinity were tested for the neutralization efficiency and
HA inhibition activity. The lower affinity scFv mutants
showed a two- to fourfold lower efficiency of neutraliza-
tion when tested on both NLFK cells (Fig. 4B) and on A72
cells (results not shown). The scFv-8 mutants also
showed reduced HA inhibition activity compared with
wild type (Table 1).
Both scFvs and MAbs aggregated virus
To investigate the neutralization mechanisms, the
scFvs or the antiviral antibodies were incubated with
125I-labeled capsids and the mixtures were then centri-
uged in sucrose gradients. The capsids without either
cFvs or antibodies formed a well-defined peak one-third
FIG. 1. The DNA and translated amino acid sequences of heavy- and
sequence are indicated as 1–3 for each chain by comparison with the
MAb 14-AF192256 and -AF192257.f the way down the gradient; however, adding poly-
lonal rabbit anti-CPV antiserum capsids caused 97.7%
a
rf the virus to be pelleted. Both scFv-8 and scFv-14
ggregated the capsids, and the aggregates increased
ith increased amounts of scFvs (Fig. 6). MAb 8 and
Ab 14 aggregated the virus, but aggregation occurred
ost efficiently at a 1:0.2 ratio of capsid VP2 to mono-
eric MAb binding site, with less aggregation at either
ivefold higher or lower ratios of IgG (Fig. 6).
cFvs or antiviral antibodies did not block virus
inding and entry to cells
In initial tests, virus was incubated with cells at 4, 20,
nd 37°C. Although binding to NLFK cells was similar at
hose three temperatures, binding to A72 cells was
arely detectable at 4°C and was greatest at 37°C (re-
ults not shown). At 4°C with NLFK cells or at 37°C with
72 cells the virus along with 1:5, 1:1, or 1:0.2 ratios of
apsid VP2 to scFv or IgG combining site showed no
ecrease in cell binding, and in most cases showed a
elative increase (Fig. 7). When cells were incubated with
irus in the presence of the antibodies, the virus was
ostly seen to be taken into cytoplasmic vesicles (Fig.
). Compared with the virus entering the cells in the
bsence of antibody, in the presence of MAbs the virus
ain variable domains of MAb 8 (A) and 14 (B). The CDR regions of each
database. GenBank accession numbers: MAb 8-U07813 and -U07814;light-chppeared as relatively large bright spots, most likely
esulting from aggregation of the virus. In the presence
474 YUAN AND PARRISHof scFvs the virus within the cells also appeared to show
some level of aggregation, although the complexes ap-
peared smaller (Fig. 8).
DISCUSSION
Here we examined the mechanisms of binding and
neutralization of CPV by scFv derived from two well-
characterized anticapsid MAbs. Each scFv showed the
FIG. 2. (A) Expression strategy of the two antibodies as single-chain
variable regions (scFv). The sequences were cloned after addition of
restriction sites to each end of the sequence, and with a (Gly4Ser)3
linker joining the two variable domains. The signal sequence and the
polyhistidine sequence were introduced from the sequence of the
pET22b(1) vector used for expression. (B and C) scFv-8 and scFv-14
amino acid sequences expressed. The pel B signal sequence, the
polyhistidine sequence, and the (Gly4Ser)3 linker are shown with italics.
The heavy- and light-chain sequences of CDR regions are underlined,
and dots indicate amino acid residues mutated in scFv-8.
FIG. 3. Binding of the scFv in ELISA to CPV (A) or FPV (B) capsids or
of the original MAb of the same antibodies, and in (C) a rabbit serum (Anti-CP
was also included.same specificity of binding as the original MAb, and both
scFv bound with a 10- to 20-fold lower efficiency com-
pared with the IgG. This was most likely a reflection of
the increased avidity of the divalent IgG compared with
the generally monovalent scFv. Interestingly, when tested
in neutralization assays, the scFvs showed an efficiency
of neutralization similar to that of the IgG (Fig. 4A). This
was similar to the effect seen for neutralization by puri-
fied Fab and IgG of the MAb 8 (Wikoff et al., 1994). The
reduced efficiency of neutralization by the scFv-8 mu-
tants indicated that the affinity of virus binding affected
its ability to neutralize.
CDR contribution to binding
To examine the contributions of the various sequences
in the scFv-8 paratope to antibody binding, we used the
cryoelectron microscopic structure of MAb 8 Fab bound
to the CPV capsid as a model (Wikoff et al., 1994). The H1
and H3 CDRs appeared to make extensive contacts with
the epitope, while H2, L1, and L3 made only minor con-
tacts (Fig. 9). We confirmed this model, as mutations
within either the H1 or H3 CDR reduced the affinity of the
scFv binding, while mutants of CDR H2 had no effect
(Fig. 5).
MAb 8 covers portions of loops 1, 2, and 3 from three
symmetry-related VP2 molecules, and most closely con-
tacted residues 87, 300, and 301 (Fig. 9). Mutations which
prevented MAb 8 binding were VP2 residue 300 Ala to
Asp or 302 Asn to Asp, while changes of 300 Ala to Gly,
298 Glu to Ala, 299 Gly to Glu, 301 Thr to Ile, or 87 Met to
Leu did not prevent antibody binding (Fig. 9) (Strassheim
et al., 1994; Parker and Parrish, 1997). The 300 Ala to Asp
mutant capsid structure shows that the Asp side chain
forms a new salt bridge with Arg 81 of an adjacent VP2,
changing the conformation of the surface loop (Fig. 9B)
(Llamas-Saiz et al., 1996). The side chain of the Asn 302
projects up from the capsid surface and likely contacts
denatured by boiling (C). The reactions are compared with the bindingto CPV
V), which recognizes both assembled and denatured capsid proteins,
were p
t
475CPV ANTIBODIES AND NEUTRALIZATIONboth heavy-chain CDR1 and CDR3, explaining why
changing that residue to Asp prevented antibody bind-
ing. These results show that the conformation of the
epitope is important for MAb 8 binding and that single
amino acids within the epitope do not affect the interac-
tion with antibody unless they change critical contacts.
HA inhibition
The scFv-8 inhibited HA with only 10-fold reduced
efficiency compared with MAb 8. However, scFv-14
showed no HA activity even at 400 nM, whereas 0.125
nM MAb 14 inhibited HA (Table 1). This difference be-
tween scFv-14 and MAb 14 appeared to be related to the
size or valency of the binding complex, because adding
an anti-Fab antibody gave HA inhibition at about 10 nM
scFv-14. The difference between scFv-8 and scFv-14 may
reflect the distance (;40 Å) between site A bound by
scFv-14 and the sialic acid binding site, while scFv-8
binds at a distance of less than 10 Å and thus would still
block sialic acid binding (Tresnan et al., 1995).
TABLE 1
Inhibition of Viral Hemagglutination by scFvs and MAbs
Antibody or scFva
HA-inhibiting concentrationb
(nM)
MAb 14 0.125
scFv 14 .400
MAb 8 0.0625
scFv-8 0.625
scFv-8 H1 2.5
scFv-8 H3 2.5
scFv-8 H1 and H3 5.0
a scFv-8 mutants H1, H3, and H1 and H3 contained changes in the VH
CDR 1 and/or CDR 3.
FIG. 4. (A) Neutralization by scFv compared with that by intact IgG o
and CDR3 of scFv-8 compared with that by wild-type scFv-8. Titrations
he presence of dilutions of the antibody are shown.b The minimum concentration of scFvs or MAbs required to inhibit
viral HA.Neutralization mechanisms
Over 30 MAbs that we have derived which recognize
intact CPV capsids neutralize the virus with varying effi-
ciency (Parrish and Carmichael, 1983; Strassheim et al.,
1994), as did the scFvs prepared here. Some of the
neutralization could be explained by aggregation of the
capsids by the scFv or MAb (Fig. 6). The mechanisms of
aggregation by the scFv were not defined, but are most
me MAb. (B) Neutralization by three mutants in the heavy-chain CDR1
erformed in NLFK cells, and the TCID50 remaining after incubation in
FIG. 5. (A) Mutations prepared within the scFv-8 heavy-chain CDRs.
Amino acid residues mutated to Ala (A) are shown in bold. (B) Effects
of scFv-8 CDR mutants on the binding to CPV capsids. Biotinylated
scFv-8 was incubated with CPV in the presence of varying amounts off the saunlabeled scFv-8 or mutant derivatives. Biotinylated scFv-8 bound was
detected with HRPO-ExtrAvidin and ABTS.
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476 YUAN AND PARRISHlikely the result of the presence of a proportion of biva-
lent scFv in the preparations resulting from intermolec-
ular associations of the scFv (Raag and Whitlow, 1995),
or perhaps to some other effect of the scFv binding
which caused the virus to aggregate. Both scFvs and
MAbs increased binding of CPV capsids to NLFK and
A72 cells, perhaps as a result of increased association of
the virus aggregates. It is therefore likely that neutraliza-
tion occurs through aggregation as well as through in-
terference with capsid transport or uncoating within cells.
Previous studies have defined neutralizing epitopes
within the capsids of CPV, pig parvovirus, and the human
parvovirus B19, and those were found within the capsid
surface, similar to the A and B sites described here, as
well as in the VP2 N-terminus of CPV and in the VP1-
unique region of B19 (Brown et al., 1992; Langeveld et al.,
1993; Saikawa et al., 1993; Casal et al., 1995; Kamstrup et
l., 1998). This is the first study to investigate the details
f the antibody-binding and neutralization mechanisms
f parvoviruses. The mechanisms are generally similar
o those reported for the neutralization of other nonen-
eloped and enveloped viruses, indicating that there are
nly a limited number of processes of neutralization for
ost viruses (Outlaw and Dimmock, 1991; Smith, 1993;
erdaguer et al., 1997; Che et al., 1998; Fleury et al., 1999;
Sattentau et al., 1999; Smith and Baker, 1999).
MATERIALS AND METHODS
Cells and viruses
NLFK cells and canine A72 cells were grown in a 1:1
FIG. 6. Aggregation of 125I-labeled CPV capsids by scFv or MAb after
incubation at various ratios for 1 h at 20°C. The mixtures were sepa-
rated in 10–40% (w/v) sucrose gradients. The 125I-CPV in the pellet and
in fractions below the free virus peak were considered to be viral
aggregates. Free capsids or capsids incubated with rabbit polyclonal
antiserum (diluted 1:400) were included as parallel controls.mixture of McCoy’s 5A and Leibovitz L15 media with 5%
fetal bovine serum (FBS). CPV-d and FPV-b were derivedfrom the infectious plasmid clones by transfection of
NLFK cells (Parrish, 1991). Capsids were purified using
previously described procedures involving polyethylene
glycol precipitation, followed by repeated banding on
10–40% sucrose gradients (Agbandje et al., 1993;
Weichert et al., 1998).
Construction of the single-chain antibodies (scFv)
Total RNA was extracted from hybridoma cell lines
secreting MAb 8 or MAb 14 (Parrish and Carmichael,
1983; Strassheim et al., 1994) by the RNAgents Total RNA
Isolation System (Promega, Madison, WI). First-strand
cDNA was synthesized using an oligo(dT) primer and
MMLV reverse transcriptase, and then the VH and VL
regions were amplified by polymerase chain reaction
(PCR), with primers either predicted by the consensus
murine k-chain sequence or from the Ig-Prime Kit (No-
vagen, Madison, WI) (Table 2). PCR products were
cloned into pT7Blue T-vector (Novagen) and sequenced
using automated DNA sequencing. The CDRs of each of
the VL and VH regions were assigned by comparison with
Kabat database (Fig. 1) (Kabat et al., 1991).
To construct scFvs the cloned VL and VH regions were
eamplified by PCR with the use of primers designed
FIG. 7. Binding of 125I-labeled CPV capsids to (A) NLFK cells at 4°C or
(B) to A72 cells at 37°C. After incubation with scFv or MAb at the ratios
shown for 1 h at 20°C, the capsids were added to the cells and incubated
for 1 h. The cells were washed and the bound 125I-labeled CPV counted.
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477CPV ANTIBODIES AND NEUTRALIZATIONfrom the sequences obtained from each variable region.
A sequence encoding (Gly4Ser)3 (Bird et al., 1988; Huston
t al., 1988) was used to link the VL and VH regions by
overlapping extension PCR (Horton et al., 1989), and then
the products were cloned in the plasmid pGEM-T (Pro-
mega). The complete scFv sequences isolated with MscI
and XhoI restriction enzymes were ligated into the vector
pET22b(1) (Novagen) (Fig. 2), adding the N-terminal pel
B leader sequence (Lei et al., 1987) and the six C-
terminal histidines to each scFv. The scFvs derived from
MAb 8 and MAb 14 were named scFv-8 and scFv-14,
respectively.
Site-directed mutagenesis of CDR sequences
of scFv-8
The contact residues in the heavy-chain CDR1 (H1),
CDR2 (H2), or CDR3 (H3) of scFv-8 were altered by
site-directed mutagenesis using specific oligonucleotide
primers and uracil-containing M13 DNA, as described by
Kunkel et al. (1987) (Fig. 5A). Double-mutant scFvs were
prepared by recombinations between the different CDRs
using intervening restriction enzyme sites (Fig. 5A). The
FIG. 8. Confocal images of virus incubated with NLFK cells in the
presence of scFv or MAb. Capsids were incubated with scFv or MAb at
20°C for 1 h, then the mixture incubated with NLFK cells for 30 min at
37°C. The cells were fixed and stained with FITC-conjugated rabbit
polyclonal anti-CPV IgG.mutated sequences were reintroduced into pET22b(1)
for expression.Expression and purification of scFvs
The E. coli strain BL21(DE3) (Novagen) containing the
scFv plasmids was grown at 30°C to an OD600 of 0.8, 0.5
M IPTG was added, and cells were cultured for 12 h at
5°C. After washing with 0.1 volume of 30 mM Tris–HCl
pH 8.0), 20% sucrose, and 1 mM EDTA, the bacteria were
xtracted with ice-cold 5 mM MgSO4 to prepare the
eriplasmic fraction (Ausubel et al., 1989). That was
made up to 20 mM Tris–HCl (pH 7.9), 500 mM NaCl, and
5 mM imidazole, and loaded onto a Ni21 His-binding
olumn (Novagen). After washing with 60 mM imidazole,
he scFvs were eluted with 1 M imidazole and dialyzed
FIG. 9. (A) A road map (Rossmann and Palmenberg, 1988) showing
the association between the B antigenic site of CPV and the Fab
footprint derived by cryoelectron microscopic analysis. The surface-
exposed regions of the four surface loops of the virus which make up
this structure are shown, along with the predicted associations with the
scFv-8 heavy-chain (H1 and H3) and light-chain (L1 and L3) CDRs.
Mutations of the virus in the footprint are indicated. Changes prevent-
ing or significantly reducing binding are boxed with solid or shaded
lines, respectively. Changes that had no effect on antibody binding are
not boxed. (B) The structural changes seen for the Ala 300 Asp mutant
of CPV in the region of the surface loop around residue 300. The
structure seen in the wild-type virus is shown with the solid line, and
the mutant structure shown with the shaded line. The Arg 81, which
makes a salt bridge with the side chain of Asp 300, is also shown in this
view of the loop. Residue 302, which is an escape mutant when
changed to Asp, projects from the surface of the capsid.
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478 YUAN AND PARRISHagainst phosphate-buffered saline (PBS, pH 7.4). The
purity of the scFv preparation was evaluated by electro-
phoresis on 12% SDS–PAGE and concentrations were
determined by Micro BCA Protein Assay Reagent Kit
(Pierce Chemicals, Rockford, IL).
ELISA testing of scFv binding
Wells of 96-well plates were incubated at 4°C with 5
mg/ml of CPV or FPV empty capsids or of capsids boiled
for 5 min. After incubation with 1% (w/v) BSA in PBS, the
plates were washed and incubated with varying dilutions
of the scFv for 1 h, and then bound scFv was detected
with goat anti-mouse IgG (Fab specific) conjugated with
horseradish peroxidase (HRPO) and the substrate 2,29-
azino-bis(3-ethylbenzthiazoline 6-sulfonic acid) diammo-
nium (ABTS). MAb 8 and MAb 14 were purified from
hybridoma supernatants by HiTrap Protein G column
(Amersham Pharmacia Biotech, Piscataway, NJ).
Relative binding affinities of scFv-8 mutants were
tested with the use of competition ELISA. The wild-type
scFv-8, biotinylated with the use of Sulfo-NHS-LS-biotin
(Pierce Chemicals), was mixed with varying concentra-
tions of unlabeled wild-type or mutant scFv-8, added to
96-well plate wells coated with CPV empty capsids, and
incubated for 1 h. After washing, the biotinylated scFv-8
bound was detected by the use of HRPO-ExtrAvidin
(Sigma, St. Louis, MO) and ABTS.
Viral neutralization assays
Purified scFvs or MAbs were diluted and incubated
with CPV-d for 1 h at 20°C. Each mixture was then
titrated in a TCID50 assay by the use of A72 cells or NLFK
cells in 96-well plates. After 48 h incubation at 37°C, the
cells were fixed with 2.5% paraformaldehyde, and in-
fected cells were detected with the use of rabbit poly-
clonal antisera against CPV capsids, HRPO-conjugated
goat anti-rabbit IgG, and the substrate aminoethyl car-
T
Primers Used to Amplify Var
Primera Se
MuIgVH59-E 59-ACTAGTCGACATGGGATG
MuIgGVH39-2 59-CCCAAGCTTCCAGGGAC
MuIgkVL59-C 59-ACTAGTCGACATGGAGTC
MuIgkVL39-1 59-CCCAAGCTTACTGGATGG
MuIgVH59-E 59-ACTAGTCGACATGGAATG
MuIgGVH39-2 59-CCCAAGCTTCCAGGGGC
Self-designed 59-GGCATCAAGATGAAGTC
Self-designed 59-GATAGGATGGAGCTGGG
a Primers MuIgVH59-E, MuIgkVL59-C, and MuIgGVH39-2 were those isbazole (AEC). TCID50 were calculated by the method of
eed and Muench (1938).
l
cnhibition of HA
Purified scFvs or MAbs were diluted and incubated
ith 4 HA units of CPV at 20°C for 1 h. Equine erythro-
ytes (0.5% v/v) in 20 mM Bis–Tris (pH 6.2) and 150 mM
aCl at 4°C were added and the plates incubated at 4°C
Barbis et al., 1992; Tresnan et al., 1995). To test the effect
f crosslinking the scFvs, they were incubated with an
qual molarity of goat anti-mouse IgG (Fab specific) for
h at 20°C, diluted, and incubated with CPV-d.
ell binding and entry
Binding of capsids to NLFK cells or A72 cells was
ssayed with CPV-d labeled with 125I (Barbis et al., 1992).
abeled capsids (0.1 mg, ;1 3 1010 particles) were in-
ubated with purified scFvs or MAbs at 1:5, 1:1, or 1:0.2
atios of capsid VP2 to antibody-combining site at 20°C
or 1 h. The cells were disassociated from culture flasks
ith a nonenzymatic disassociation solution and washed
ith DMEM. The CPV/antibody mixture was incubated in
MEM and 0.1% bovine serum albumin with 1 3 105
NLFK cells at 4°C, or with A72 cells at 37°C. After 1 h the
cells were washed in the same buffer and the bound 125I
was counted.
CPV capsids (40 mg/ml) were mixed and incubated
with the scFv or MAb at 20°C for 1 h, then added to NLFK
or A72 cells. After 30-min incubation at 37°C the cells
were fixed with 2.5% paraformaldehyde in PBS and
stained with an FITC-conjugated rabbit polyclonal IgG
against the CPV capsid. The cells were observed by
confocal microscopy and optical sections collected from
the center of the cells.
Aggregation of capsids by scFvs or MAbs
scFvs or MAbs were incubated at 20°C for 1 h with
125I-labeled CPV-d at 1:1, 1:0.2, or 1:0.04 ratios of capsid
P2 to scFv or MAb combining site. Mixtures were
omains of MAb from cDNA
e
GGGGTCTTTCTCTT-39 VH of MAb 8
GATAAACGGATGG-39 VH of MAb 8
ACACTCCTGTTATGGGT-39 VL of MAb 8
AAGATGGA-39 VL of MAb 8
GGGGTCTTTCTCTT-39 VH of MAb 14
GATAAACGGGTGG-39 VH of MAb 14
-39 VL of MAb 14
39 VL of MAb 14
in the cDNA clones prepared.ABLE 2
iable D
quenc
GAGC
CAGTG
AGAC
TGGG
GAGC
CAATG
ACAGA
GAGC-oaded onto 10 to 40% sucrose gradients in DMEM and
entrifuged in a SW41 rotor at 36,000 rpm for 2.5 h, the
f
c
f
479CPV ANTIBODIES AND NEUTRALIZATIONgradients were fractionated, and the 125I DPM in each
raction or in the pellet was determined. The aggregated
apsids were determined as those in the pellet or in the
ractions below the peak of free virus.
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